Robotic catheter brings autonomous navigation into human body

 

Robotic catheter brings autonomous navigation into the human body

Concentric tube robot. In a recent demo, robotic catheter autonomously found its way to a leaky heart valve. Source: Pediatric Cardiac Bioengineering Lab, Department of Cardiovascular Surgery, Boston Children’s Hospital, Harvard Medical School

BOSTON — Bioengineers at Boston Children’s Hospital said they successfully demonstrated for the first time a robot able to navigate autonomously inside the body. In a live pig, the team programmed a robotic catheter to find its way along the walls of a beating, blood-filled heart to a leaky valve — without a surgeon’s guidance. They reported their work today in Science Robotics.

Surgeons have used robots operated by joysticks for more than a decade, and teams have shown that tiny robots can be steered through the body by external forces such as magnetism. However, senior investigator Pierre Dupont, Ph.D., chief of Pediatric Cardiac Bioengineering at Boston Children’s, said that to his knowledge, this is the first report of the equivalent of a self-driving car navigating to a desired destination inside the body.

Pierre Dupont

Pierre Dupont, chief of Pediatric Cardiac Bioengieering at Boston Children’s Hospital

Dupont said he envisions autonomous robots assisting surgeons in complex operations, reducing fatigue and freeing surgeons to focus on the most difficult maneuvers, improving outcomes.

“The right way to think about this is through the analogy of a fighter pilot and a fighter plane,” he said. “The fighter plane takes on the routine tasks like flying the plane, so the pilot can focus on the higher-level tasks of the mission.”

Touch-guided vision, informed by AI

The team’s robotic catheter navigated using an optical touch sensor developed in Dupont’s lab, informed by a map of the cardiac anatomy and preoperative scans. The touch sensor uses artificial intelligence and image processing algorithms to enable the catheter to figure out where it is in the heart and where it needs to go.

For the demo, the team performed a highly technically demanding procedure known as paravalvular aortic leak closure, which repairs replacement heart valves that have begun leaking around the edges. (The team constructed its own valves for the experiments.) Once the robotic catheter reached the leak location, an experienced cardiac surgeon took control and inserted a plug to close the leak.

In repeated trials, the robotic catheter successfully navigated to heart valve leaks in roughly the same amount of time as the surgeon (using either a hand tool or a joystick-controlled robot).

Biologically inspired navigation

Through a navigational technique called “wall following,” the robotic catheter’s optical touch sensor sampled its environment at regular intervals, in much the way insects’ antennae or the whiskers of rodents sample their surroundings to build mental maps of unfamiliar, dark environments. The sensor told the catheter whether it was touching blood, the heart wall or a valve (through images from a tip-mounted camera) and how hard it was pressing (to keep it from damaging the beating heart).

Data from preoperative imaging and machine learning algorithms helped the catheter interpret visual features. In this way, the robotic catheter advanced by itself from the base of the heart, along the wall of the left ventricle and around the leaky valve until it reached the location of the leak.

“The algorithms help the catheter figure out what type of tissue it’s touching, where it is in the heart, and how it should choose its next motion to get where we want it to go,” Dupont explained.

Though the autonomous robot took a bit longer than the surgeon to reach the leaky valve, its wall-following technique meant that it took the longest path.

“The navigation time was statistically equivalent for all, which we think is pretty impressive given that you’re inside the blood-filled beating heart and trying to reach a millimeter-scale target on a specific valve,” said Dupont.

He added that the robot’s ability to visualize and sense its environment could eliminate the need for fluoroscopic imaging, which is typically used in this operation and exposes patients to ionizing radiation.

Robot ercutaneous access to the heart, from Pediatric Cardiac Bioengineering Lab

Robotic catheter enters internal jugular vein and navigates through the vasculature into the right atrium. Source: Pediatric Cardiac Bioengineering Lab

A vision of the future?

Dupont said the project was the most challenging of his career. While the cardiac surgical fellow, who performed the operations on swine, was able to relax while the robot found the valve leaks, the project was taxing for Dupont’s engineering fellows, who sometimes had to reprogram the robot mid-operation as they perfected the technology.

“I remember times when the engineers on our team walked out of the OR completely exhausted, but we managed to pull it off,” said Dupont. “Now that we’ve demonstrated autonomous navigation, much more is possible.”

Some cardiac interventionalists who are aware of Dupont’s work envision using robots for more than navigation, performing routine heart-mapping tasks, for example. Some envision this technology providing guidance during particularly difficult or unusual cases or assisting in operations in parts of the world that lack highly experienced surgeons.

As the U.S. Food and Drug Administration begins to develop a regulatory framework for AI-enabled devices, Dupont said that autonomous surgical robots all over the world could pool their data to continuously improve performance over time — much like self-driving vehicles in the field send their data back to Tesla to refine its algorithms.

“This would not only level the playing field, it would raise it,” said Dupont. “Every clinician in the world would be operating at a level of skill and experience equivalent to the best in their field. This has always been the promise of medical robots. Autonomy may be what gets us there.”

Boston Children's Hospital

Boston Children’s Hospital in the Longwood Medical Area. Photo by Jenna Lang.

About the paper

Georgios Fagogenis, PhD, of Boston Children’s Hospital was first author on the paper. Coauthors were Margherita Mencattelli, PhD, Zurab Machaidze, MD, Karl Price, MaSC, Viktoria Weixler, MD, Mossab Saeed, MB, BS, and John Mayer, MD of Boston Children’s Hospital; Benoit Rosa, PhD, of ICube, Universite? de Strasbourg (Strasbourg, France); and Fei-Yi Wu, MD, of Taipei Veterans General Hospital, Taipei, Taiwan. For more on the technology, contact TIDO@childrenshospital.org.

The study was funded by the National Institutes of Health (R01HL124020), with partial support from the ANR/Investissement d’avenir program. Dupont and several of his coauthors are inventors on U.S. patent application held by Boston Children’s Hospital that covers the optical imaging technique.

About Boston Children’s Hospital

Boston Children’s Hospital, the primary pediatric teaching affiliate of Harvard Medical School, said it is home to the world’s largest research enterprise based at a pediatric medical center. Its discoveries have benefited both children and adults since 1869. Today, more than 3,000 scientists, including 8 members of the National Academy of Sciences, 18 members of the National Academy of Medicine and 12 Howard Hughes Medical Investigators comprise Boston Children’s research community.

Founded as a 20-bed hospital for children, Boston Children’s is now a 415-bed comprehensive center for pediatric and adolescent health care. For more, visit the Vector and Thriving blogs and follow it on social media @BostonChildrens@BCH_Innovation, Facebook and YouTube.

Robotics investments recap: March 2019

CloudMinds was among the robotics companies receiving funding in March 2019.

CloudMinds was among the robotics companies receiving funding in March 2019. Source: CloudMinds

Investments in robots, autonomous vehicles, and related systems totaled at least $1.3 billion in March 2019, down from $4.3 billion in February. On the other hand, automation companies reported $7.8 billion in mergers and acquisitions last month. While that may represent a slowdown, note that many businesses did not specify the amounts involved in their transactions, of which there were at least 58 in March.

Self-driving cars and trucks — including machine learning and sensor technologies — continued to receive significant funding. Although Lyft’s initial public offering was not directly related to autonomous vehicles, it illustrates the investments flowing for transportation.

Other use cases represented in March 2019 included surgical robotics, industrial automation, and service robots. See the table below, which lists amounts in millions of dollars where they were available:

CompanyAmt. (M$)TypeLead investor, partner, acquirerDateTechnology
Airbiquity15investmentDenso Corp., Toyota Motor Corp., Toyota Tsushu Corp.March 12, 2019connected vehicles
AROMA BIT Inc.2.2Series ASony Innovation FundMarch 3, 2019olofactory sensors
AtomRobotSeries B1Y&R CapitalMarch 5, 2019industrial automation
Automata7.4Series AABB March 19, 2019robot arm
Avidbots23.6Series BTrue VenturesMarch 21, 2019commercial floor cleaning
BoranetSeries AGobi PartnersMarch 6, 2019IIoT, machine vision
Broadmann1711Series AOurCrowdMarch 6, 2019deep learning, autonomous vehicles
Cloudminds300investmentSoftBank Vision FundMarch 26, 2019service robots
Corindus4.8private placementMarch 12, 2019surgical robot
Determined AI11Series AGV (Google Ventures)March 13, 2019AI, deep learning
Emergen Group29Series BQiming Venture PartnersMarch 13, 2019industrial automation
Fabu Technologypre-Series AQingsong FundMarch 1, 2019autonomous vehicles
FortnarecapitalizationThomas H. Lee PArtners LPMarch 27, 2019materlais handling
ForwardX14.95Series BHupang Licheng FundMarch 21, 2019autonomous mobile robots
Gaussian Robotics14.9Series BGrand Flight InvestmentMarch 20, 2019cleaning
Hangzhou Guochen Robot Technology15Series AHongcheng Capital, Yingshi Fund (YS Investment) March 13, 2019robotics R&D
Hangzhou Jimu Technology Co.Series BFlyfot VenturesMarch 6, 2019autonomous vehicles
InnerSpace3.2seedBDC Capital's Women in Technology FundMarch 26, 2019IoT
Innoviz Technologies132Series CChina Merchants Capital, Shenzhen Capital Group, New Alliance CapitalMarch 26, 2019lidar
Intelligent MarkinginvestmentBenjamin CapitalMarch 6, 2019autonomous robots for marking sports fields
Kaarta Inc.6.5Series AGreenSoil Building Innovation FundMarch 21, 2019lidar mapping
Kolmostar Inc.10Series AMarch 5, 2019positioning technology
Linear Labs4.5seedScience Inc., Kindred VenturesMarch 26, 2019motors
MELCO Factory Automation Philippines Inc.2.38new divisionMitsubishi Electric Corp.March 12, 2019industrial automation
Monet Technologies4.51joint ventureHonda Motor Co., Hino Motors Ltd., SoftBank Corp., Toyota Motor CorpMarch 28, 2019self-driving cars
Ouster60investmentRunway Growth Capital, Silicon Valley BankMarch 25, 2019lidar
Pickle Robot Co.3.5equity saleMarch 4, 2019loading robot
Preteckt2seedLos Olas Venture CapitalMarch 26, 2019machine learning automotive
Radar16investmentSound Ventures, NTT Docomo Ventures, Align Ventures, Beanstalk Ventures, Colle Capital, Founders Fund Pathfinder, Novel TMTMarch 28, 2019RFID inventory management
Revvo (IntelliTire)4Series ANorwest Venture PartnersMarch 26, 2019smart tires
Shanghai Changren Information Technology14.89Series AMarch 15, 2019Xiaobao healthcare robot
TakeOff Technologies Inc.equity saleMarch 26, 2019grocery robots
TartanSense2seedOmnivore, Blume Ventures, BEENEXTMarch 11, 2019weeding robot
Teraki2.3investmentHorizon Ventures, American Family VenturesMarch 27, 2019AI, automotive electronics
Think Surgical134investmentMarch 11, 2019surgical robot
Titan Medical25IPOMarch 22, 2019surgical robotics
TMiRobSeries B+Shanghai Zhangjiang Torch Venture Capital March 26, 2019hospital robot
TOYO Automation Co.investmentYamaha Motor Co.March 20, 2019actuators
UbtechinvestmentLiangjiang CapitalMarch 6, 2019humanoid
Vintra4.8investmentBonfire Ventures, Vertex Ventures, London Venture PartnersMarch 11, 2019machine vision
Vtrus2.9investmentMarch 8, 2019drone inspection
Weltmeister Motor450Series CBaidu Inc.March 11, 2019self-driving cars

And here are the mergers and acquisitions:

March 2019 robotics acquisitions

CompanyAmt. (M$)AcquirerDateTechnology
Accelerated DynamicsAnimal Dynamics3/8/2019AI, drone swarms
Astori AS4Subsea3/19/2019undersea control systems
BrainlabSmith & Nephew3/12/2019surgical robot
Figure Eight175Appen Ltd.3/10/2019AI, machine learning
Floating Point FXCycloMedia3/7/2019machine vision, 3D modeling
Florida Turbine Technologies60Kratos Defense and Security Solutions3/1/2019drones
Infinity Augmented RealityAlibaba Group Holding Ltd.3/21/2019AR, machine vision
Integrated Device Technology Inc.6700Renesas3/30/2019self-driving vehicle processors
MedineeringBrainlab3/20/2019surgical
Modern Robotics Inc.0.97Boxlight Corp.3/14/2019STEM
OMNI Orthopaedics Inc.Corin Group3/6/2019surgical robotics
OrthoSpace Ltd.220Stryker Corp.3/14/2019surgical robotics
Osiris Therapeutics660Smith & Nephew3/12/2019surgical robotics
Restoration Robotics Inc.21Venus Concept Ltd.3/15/2019surgical robotics
Sofar Ocean Technologies7Spoondrift, OpenROV3/28/2019underwater drones, sensors
Torc Robotics Inc.Daimler Trucks and Buses Holding Inc.3/29/2019driverless truck software

Surgical robots make the cut

One of the largest transactions reported in March 2019 was Smith & Nephew’s purchase of Osiris Therapeutics for $660 million. However, some Osiris shareholders are suing to block the acquisition because they believe the price that U.K.-based Smith & Nephew is offering is too low. The shareholders’ confidence reflects a hot healthcare robotics space, where capital, consolidation, and chasing new applications are driving factors.

In the meantime, Stryker Corp. bought sports medicine provider OrthoSpace Ltd. for $220 million. The market for sports medicine will experience a compound annual growth rate of 8.9% between now and 2023, predicts Market Research Future.

Freemont, Calif.-based Think Surgical raised $134 million for its robot-assisted orthopedic surgical device, and Titan Medical closed a $25 million public offering last month.

Venus Concept Ltd. merged with hair-implant provider Restoration Robotics for $21 million, and Shanghai Changren Information Technology raised Series A funding of $14.89 million for its Xiaobao healthcare robot.

Corindus Vascular Robotics Inc. added $5 million to the $15 million it had raised the month before. Brainlab acquired Medineering and was itself acquired by Smith & Nephew.

Driving toward automation in March 2019

Aside from Lyft, the biggest reported transportation robotics transaction in March 2019 was Renesas’ completion of its $6.7 billion purchase of Integrated Device Technology Inc. for its self-driving car chips.

The next biggest deal was Weltmeister Motor’s $450 million Series C, in which Baidu Inc. participated.

Lidar also got some support, with Innoviz Technologies raising $132 million in a Series C round, and Ouster raising $60 million. In a prime example of how driverless technology is “paying a peace dividend” to other applications, Google parent Alphabet’s Waymo unit offered its custom lidar sensors to robotics, security, and agricultural companies.

Automakers recognize the need for 3-D modeling, sensors, and software for autonomous vehicles to navigate safely and accurately. A Daimler unit acquired Torc Robotics Inc., which is working on driverless trucks, and CycloMedia acquired machine vision firm Floating Point FX. The amounts were not specified.

Speaking of machine learning, Appen Ltd. acquired dataset annotation company Figure Eight for $175 million, with an possible $125 million more based on 2019 performance. Denso Corp. and Toyota Motor Corp. contributed $15 million to Airbiquity, which is working on connected vehicles.

Service robots clean up

From retail to cleaning and customer service, the combination of improving human-machine interactions, ongoing staffing turnover and shortages, and companies with round-the-clock operations has contributed to investor interest.

The SoftBank Vision Fund participated in a $300 million round for CloudMinds. The Chinese AI and robotics company’s XR-1 is a humanoid service robot, and it also makes security robots and connects robots to the cloud.

According to its filing with the U.S. Securities and Exchange Commission, TakeOff Technologies Inc. raised an unspecified amount for its grocery robots, an area that many observers expect to grow as consumers become more accustomed to getting home deliveries.

On the cleaning side, Avidbots raised $23.6 million in Series B, led by True Ventures. Gaussian Robotics’ Series B was $14.9 million, with participation from Grand Flight Investment.

Robotics Summit & Expo 2019 logoKeynotes | Speakers | Exhibitors | Register

Wrapping up Q1 2019

China’s efforts to develop its domestic robotics industry continued, as Emergen Group’s $29 million Series B round was the largest reported investment in industrial automation last month.

Hangzhou Guochen Robot Technology raised $15 million in Series A funding for robotics research and development and integration.

That was followed by ABB’s participation in Series A funding of $7.4 million for Automata, which makes a small collaborative robot arm named Ava. Mitsubishi Electric Corp. said it’s spending $2.38 million to set up a new company, MELCO Factory Automation Philippines Inc., because it expects to grow its business there to $30 million by 2026.

Data startup Spopondrift and underwater drone maker OpenROV merged to form Sofar Ocean Technologies. The new San Francisco company also announced a Series A round of $7 million. Also, 4Subsea acquired underwater control systems maker Astori AS.

In the aerial drone space, Kratos Defense and Security Solutions acquired Florida Turbine Technologies for $60 million, and Vtrus raised $2.9 million for commercializing drone inspections. Kaarta Inc., which makes a lidar for indoor mapping, raised $6.5 million.

The Robot Report broke the news of Aria Insights, formerly known as CyPhy Works, shutting down in March 2019.


Editors Note: What defines robotics investments? The answer to this simple question is central in any attempt to quantify robotics investments with some degree of rigor. To make investment analyses consistent, repeatable, and valuable, it is critical to wring out as much subjectivity as possible during the evaluation process. This begins with a definition of terms and a description of assumptions.

Investors and Investing
Investment should come from venture capital firms, corporate investment groups, angel investors, and other sources. Friends-and-family investments, government/non-governmental agency grants, and crowd-sourced funding are excluded.

Robotics and Intelligent Systems Companies
Robotics companies must generate or expect to generate revenue from the production of robotics products (that sense, think, and act in the physical world), hardware or software subsystems and enabling technologies for robots, or services supporting robotics devices. For this analysis, autonomous vehicles (including technologies that support autonomous driving) and drones are considered robots, while 3D printers, CNC systems, and various types of “hard” automation are not.

Companies that are “robotic” in name only, or use the term “robot” to describe products and services that that do not enable or support devices acting in the physical world, are excluded. For example, this includes “software robots” and robotic process automation. Many firms have multiple locations in different countries. Company locations given in the analysis are based on the publicly listed headquarters in legal documents, press releases, etc.

Verification
Funding information is collected from a number of public and private sources. These include press releases from corporations and investment groups, corporate briefings, and association and industry publications. In addition, information comes from sessions at conferences and seminars, as well as during private interviews with industry representatives, investors, and others. Unverifiable investments are excluded.

The post Robotics investments recap: March 2019 appeared first on The Robot Report.

Smith & Nephew teases next-gen surgical robotics platform


Navio

Navio robotic-assisted surgery system. (Credit: Smith & Nephew)

Smith & Nephew has acquired Brainlab‘s orthopedic joint reconstruction business and teased the unveiling of a next-generation surgical robotics platform for later in 2019.

The London-based company said that its acquisition of Brainlab’s orthopaedic joint reconstruction business included its associated salesforce, which it plans to fold into its surgical robotics division. It added that it will look to install Brainlab’s hip software onto its currently-in-development Navio 7.0 handheld surgical system, which it plans to release during the second half of this year.

Along with the acquisition, Smith & Nephew said that it inked a collaborative development deal with Brainlab to develop additional applications for its advanced automation platform.

Related: Think Surgical raises $134M for TSolution One robotics platform

“The near-term commercial opportunities with the innovation of our robotics platform and the integration of the Brainlab hip software are very compelling. Not to mention, the strong collaboration on design and development of next generation technology that will bring our customers more differentiated advanced surgical capabilities. We’re excited to work together with Brainlab to bring the future of the digitally integrated O.R. to life and into the hands of surgeons world-wide,” Skip Kiil, President, Global Orthopeadics, Smith & Nephew said in a prepared statement.


Robotics Summit & Expo 2019 logoKeynotes | Speakers | Exhibitors | Register


In the same release, the company said that it expects to complete development of its next-generation surgical robotics platform some time later this year, with a full commercial release in 2020. It teased that the new platform will have a dramatically reduced footprint and be able to be incorporated into the company’s sports medicine tower, and that the system will be faster than its still-in-development Navio 7.0.

Smith & Nephew added that its research & development program is looking to add augmented reality, stand-alone robotic arms and machine learning to the platform, and that it plans to open a new R&D and education center focused on robotics in Pittsburgh.

“Smith & Nephew is making a long-term commitment to bring together advanced technologies in robotics, digital surgery, and machine learning as well as augmented reality to empower surgeons and improve clinical outcomes. Over time these digital surgery and robotic assets will be deployed across all surgical specialities and healthcare settings where Smith & Nephew’s operates, starting with orthopaedic reconstruction and sports medicine,” CEO Namal Nawana said in a press release.

The post Smith & Nephew teases next-gen surgical robotics platform appeared first on The Robot Report.

FDA warns about using surgical robots for cancer treatment



Robotics Summit & Expo 2019 logoKeynotes | Speakers | Exhibitors | Register


The U.S. Food and Drug Administration (FDA) has issued a warning against the use of surgical robots in mastectomies and other surgeries for the treatment or prevention of cancer.

The FDA said the safety and effectiveness of surgical robots have not been established for use in mastectomies or for surgeries to prevent or treat breast and other cancers. The FDA said it “encourages health care providers who use robotically-assisted surgical devices to have specialized training and practice in their use.”

The warning follows the publication of a study in the New England Journal of Medicine that said robot-assisted cervical cancer surgeries had reduced survival than open abdominal radical hysterectomies among women with early-stage cervical cancer. The journal article noted that other researchers have reported no statistically significant difference in long-term survival when these types of surgical procedures are compared.

Separately, a New Jersey hospital suspended robot-assisted mastectomy after it publicized two such procedures performed by one of its surgeons, concluding the surgery needs further review, according to a report in the Asbury Park Press. Long Island, N.Y.-based Northwell Health also touted the robot-assisted double mastectomy performed on a woman who carried the BRCA gene, which is associated with developing breast cancer.

Advocates of such robot-assisted surgery say it’s less invasive and causes less pain and fewer scars for patients. Critics such as Hooman Noorchashm, a Philadelphia-area surgeon-turned-patient-advocate, say that robot-assisted procedures are very different from standard surgery.

“If you’re dramatically changing existing standards of care… you better demonstrate that it’s not inferior to existing standards before you advertise it,” Noorchashm said in an interview with Medical Design & Outsourcing, a sister website of The Robot Report.

Demonstrating non-inferiority would traditionally require clinical trials comparing the outcomes of robotic-assisted versus standard surgery. Such studies on breast cancer patients are underway in France and Italy, but none have occurred in the United States. French investigators are comparing outcomes using traditional surgery and Intuitive Surgical’s da Vinci Robot Xi, according to the trial’s listing on clinicaltrials.gov.

“To date, the FDA’s evaluation of robotically assisted surgical devices has generally focused on determining whether the complication rate at 30 days is clinically comparable to other surgical techniques,” the agency’s warning says. “To evaluate robotically-assisted surgical devices for use in the prevention or treatment of cancer, including breast cancer, the FDA anticipates these uses would be supported by specific clinical outcomes, such as local cancer recurrence, disease-free survival, or overall survival at time periods much longer than 30 days.”

The agency has not granted marketing authorization for any robot-assisted surgical device for use in the United States for the prevention or treatment of cancer, including breast cancer. The labeling for robotic surgical devices that are legally marketed in the United States includes statements that cancer treatment outcomes using the device have not been evaluated by FDA.

“Health care providers and patients should consider the benefits, risks and alternatives to robotically assisted surgical procedures and consider this information to make informed treatment decisions,” the agency’s warning said.

The industry leader in robot-assisted surgery, Intuitive promotes the use of its robots for hysterectomies, both benign and cancer-related, on its website. The company does not list mastectomy among da Vinci’s recommended procedures and FDA did not mention Intuitive or any other surgical robotics company in its warning.

“Minimally invasive surgical devices, including robotic-assisted surgical systems and laparoscopic surgical tools, are cleared by the FDA for specific procedures, such as prostatectomy and hysterectomy, not specifically for cancer prevention or treatment,” Intuitive Surgical said in an email. “To date, there are more than 15,000 peer-reviewed articles that, in aggregate, support the safety and effectiveness of robotic-assisted surgery. We value the FDA’s role in protecting and promoting public health, and will continue to look to the agency for guidance as we develop innovative solutions for surgeons and their patients.”

A Danish study published this week in JAMA Surgery said that the risk of severe complications among early-stage endometrial cancer patients who underwent surgery after the national introduction of minimally invasive robotic surgery was significantly reduced. The patients with better outcomes included those whose procedures were minimally invasive laparoscopic surgeries and those who underwent robot-assisted surgeries. Patients were followed for 90 days post-procedure.

Intuitive Surgical recommended that surgeons discuss all treatment options with their patients and that patients ask surgeons about their training, experience, and patient outcomes.

Noorchashm’s wife, Dr. Amy Reed, died in 2017, four years after a myomectomy of fibroid tumors using a power morcellator. The tumors turned out to be a malignant form of cancer called uterine sarcoma that’s difficult to distinguish from benign tumors.

Noorchashm said he’s not anti-innovation but wants surgeons to proceed with caution. “They should slow the hell down,” he said.

Editor’s Note: This article was originally published on our sister website Medical Design & Outsourcing.

The post FDA warns about using surgical robots for cancer treatment appeared first on The Robot Report.